Diadem spa announces exclusive u.s. licensing agreement with quest diagnostics for its alzosure® predict alzheimer's disease prognostic technology

—quest to develop and market a lab-developed test based on the ip of alzosure predict® in the united states, extending its industry-leading portfolio of alzheimer's disease blood tests— —validating clinical data suggests that alzosure® predict's blood-based technology can help identify whether or not individuals will progress to alzheimer's disease up to 6 years before diagnosis— milan and secaucus, n.j., oct. 25, 2023 /prnewswire/ -- diadem spa, (diadem), a company developing one of the first blood-based tests for the early and accurate prediction of clinical progression to alzheimer's disease (ad), today announced that it has formed a strategic collaboration with quest diagnostics (nyse: dgx), the nation's leading provider of diagnostic information services, designed to improve access to high quality blood tests for evaluating the risk of alzheimer's disease.
DGX Ratings Summary
DGX Quant Ranking